BAUSCH & LOMB STREAMLINING EFFORT INCLUDES JOB CUTS OF 1,500
This article was originally published in The Gray Sheet
Executive SummaryBAUSCH & LOMB STREAMLINING EFFORT INCLUDES JOB CUTS OF 1,500 employees, two-thirds of whom are in the firm's contact lens and sunglass businesses. The remaining cuts will come from B&L's other product areas, which include ophthalmic pharmaceuticals, OTC drugs, dental implants, skin care products, and sports optics. Representing about 10% of B&L's worldwide workforce of 15,900 employees as of January, the reduction in employment started earlier this year and is expected to be nearly completed by the end of the third quarter.
You may also be interested in...
Biogen value-based contract with UPMC Health Plan ties payments to patient-reported outcomes for Tecfidera and Avonex. The company may seek something similar for Vumerity.
As interest in immune/inflammatory disease increases and savings achieved dip, payer focus on patient-reported outcomes for contracts reflects shift in focus, Avalere survey suggests.
After an eleventh-hour win last year that saw Congress repeal the medical device excise tax, AdvaMed is going more global. CEO Scott Whitaker sat down with Medtech Insight for a lengthy chat about what the lobby group will focus on in 2020, including reimbursement challenges, the upcoming medical device user-fee negotiations, and negotiations with governments that are key to the industry ecosystem.